{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03968211",
      "orgStudyIdInfo": {
        "id": "21453"
      },
      "organization": {
        "fullName": "University of Virginia",
        "class": "OTHER"
      },
      "briefTitle": "Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency",
      "officialTitle": "Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-03",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2019-07-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2023-12-31",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2023-12-31",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2019-05-28",
      "studyFirstSubmitQcDate": "2019-05-29",
      "studyFirstPostDateStruct": {
        "date": "2019-05-30",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-03-28",
      "lastUpdatePostDateStruct": {
        "date": "2024-03-29",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Larry Borish, MD",
        "investigatorTitle": "Professor of Medicine and Microbiology",
        "investigatorAffiliation": "University of Virginia"
      },
      "leadSponsor": {
        "name": "University of Virginia",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "CSL Behring",
          "class": "INDUSTRY"
        },
        {
          "name": "Jeffrey Modell Foundation",
          "class": "UNKNOWN"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": true
    },
    "descriptionModule": {
      "briefSummary": "This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a biomarker, or early sign of, the development of immune deficiency.",
      "detailedDescription": "IgE is the antibody thought to be responsible for developing allergies. Undetectable serum IgE (an IgE below the lower limit of detection) is found in about 3% of the general population. In the past, it has been thought that having an undetectable IgE does not have any health impact, other than meaning that you are at low risk for having allergies. However, recent studies of patients with undetectable IgE have shown higher rates of infections, autoimmune disease and cancer.\n\nPatients with an immune deficiency called common variable immunodeficiency (CVID) also have higher rates of infections, autoimmune disease and cancer. Recently, we have shown that most patients with CVID have a low/undetectable serum IgE.\n\nThis study is trying to find out if an undetectable serum IgE is a biomarker, or early sign of, the development of CVID or other antibody deficiencies"
    },
    "conditionsModule": {
      "conditions": [
        "Immune Deficiency"
      ],
      "keywords": [
        "immunodeficiency",
        "IgE"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "DIAGNOSTIC",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 37,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Vaccine",
          "type": "EXPERIMENTAL",
          "description": "Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine",
          "interventionNames": [
            "Biological: Salmonella typhi polysaccharide vaccine"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Salmonella typhi polysaccharide vaccine",
          "description": "Salmonella typhi polysaccharide vaccine",
          "armGroupLabels": [
            "Vaccine"
          ],
          "otherNames": [
            "Typhim Vi"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Vaccination response",
          "description": "IgG to Salmonella typhi will be measured, with a normal response calculated as at least a 2-fold increase in IgG titers post-vaccination",
          "timeFrame": "4-6 weeks"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Epsilon germline transcript production",
          "description": "B cells isolated from subjects will be evaluated to determine their ability to produce Epsilon germline transcript in response to stimulation",
          "timeFrame": "3 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Age 18-80\n* Willingness and ability to comply with scheduled visits and study procedures\n* Undetectable serum IgE (defined as \\>2 IU/mL or the lower threshold of detection)\n* Normal or high serum immunoglobulins (within or above laboratory reference range for IgG, IgA, and IgM)\n* patients previously seen at the University of Virginia Asthma, Allergy, and Immunology clinics where undetectable serum IgE was noted\n* Control subjects must have participated in study IRB#14457 (only applicable for healthy controls in epsilon germline transcript portion of the study)\n\nExclusion Criteria:\n\n* The following vulnerable populations will be excluded: pregnant women, fetuses, neonates, children, prisoners, cognitively impaired, educational or economically disadvantaged, non-English speaking subjects\n* Known personal history of immunodeficiency\n* Known personal history of recurrent infections\n* Low serum immunoglobulins (below the laboratory reference range for IgG, IgA, or IgM)\n* Recent or current treatment with systemic immunosuppression within the past 30 days",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "80 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Larry Borish, MD",
          "affiliation": "University of Virginia",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "University of Virginia Health System",
          "city": "Charlottesville",
          "state": "Virginia",
          "zip": "22908",
          "country": "United States",
          "geoPoint": {
            "lat": 38.02931,
            "lon": -78.47668
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "29453744",
          "type": "BACKGROUND",
          "citation": "Lawrence MG, Palacios-Kibler TV, Workman LJ, Schuyler AJ, Steinke JW, Payne SC, McGowan EC, Patrie J, Fuleihan RL, Sullivan KE, Lugar PL, Hernandez CL, Beakes DE, Verbsky JW, Platts-Mills TAE, Cunningham-Rundles C, Routes JM, Borish L. Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID). J Clin Immunol. 2018 Apr;38(3):225-233. doi: 10.1007/s10875-018-0476-0. Epub 2018 Feb 17."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "YES",
      "description": "De-identified IPD that underlie results in a publication will be made available upon request of another researcher or if required by the publisher",
      "infoTypes": [
        "STUDY_PROTOCOL",
        "SAP",
        "CSR"
      ],
      "timeFrame": "Starting 6 months after publication"
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "ICF",
          "hasProtocol": false,
          "hasSap": false,
          "hasIcf": true,
          "label": "Informed Consent Form",
          "date": "2019-05-24",
          "uploadDate": "2023-03-06T10:12",
          "filename": "ICF_000.pdf",
          "size": 824773
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D007153",
          "term": "Immunologic Deficiency Syndromes"
        }
      ],
      "ancestors": [
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C057664",
          "term": "Vi polysaccharide vaccine, typhoid"
        }
      ]
    }
  },
  "hasResults": false
}